The findings and conclusions in these presentations have not been formally disseminated by the Centers for Disease Control and Prevention and should not be construed to represent any agency determination or policy.

Tuesday, March 11, 2008 - 10:15 AM
A8c

Chlamydia and Gonorrhea Infection among Female Family Planning Clients Diagnosed with Pelvic Inflammatory Disease in California, 2003-2005

Joan M. Chow1, Jian-tong Guo2, Michael C. Samuel3, K. Sisco4, S. Steinberg5, Laurie Weaver5, and Gail Bolan6. (1) Sexually Transmitted Disease Control Branch, California Department of Public Health, 850 Marina Bay Parkway, Building P, Second Floor, Richmond, CA, USA, (2) Sexually Transmitted Disease Control Branch, California Department of Health Services, 850 Marina Bay Parkway, Building P, Second Floor, Richmond, CA, USA, (3) STD Control Branch, California Department of Health Services, 850 Marina Bay Parkway, Building P. 2nd Floor, Richmond, CA, USA, (4) Quest Diagnostics, Inc, 18408 Oxnard Street, Tarzana, CA, USA, (5) Maternal, Child, Adolescent Health/Office of Family Planning, California Department of Health Services, 1615 Capitol Avenue, MS 8300, P.O. Box 997420, Sacramento, CA, USA, (6) STD Control Branch, California Department of Public Health, 850 Marina Bay Parkway, Building P, 2nd Floor, Richmond, CA, USA


Background:
Out-patient visits associated with pelvic inflammatory disease (PID) decreased in the US since 1996. It is unknown if the prevalence of current chlamydia (CT) and gonorrhea (GC) remains common among out-patient PID cases.

Objective:
To estimate current CT/GC prevalence among family planning (FP) clinic PID cases.

Method:
We linked Quest Diagnostics CT/GC test results (1/1/03-12/31/05) for female FP clients in the California Family PACT program to paid claims with ICD-9 codes and pharmacy claims associated with PID. We calculated age-specific “current” CT/GC prevalence using test results on dates ±7 days of the PID diagnosis date.

Result:
There were 39 providers that used Quest Diagnostics for CT/GC testing and linked to 391 PID cases of whom 84% had current CT/GC test results. Females age ≤ 25 years comprised 50.1% of PID cases. Among 328 PID cases with “current” CT tests, the prevalence of CT was 9.7% and significantly higher among cases age ≤25 years (16.6%) compared with older clients (3.0%). Among 315 PID cases with “current” GC tests, 1.6% were GC-positive with prevalence highest among cases age ≤20 years (5.7%) compared with older cases (1.9% among cases age 21-25; 0.0% among cases age >25 years). Three clients were co-infected with CT and GC.

Conclusion:
Higher prevalence among young PID cases supports screening of young women to identify upper and lower genital tract CT/GC. The high proportion of PID cases and the lower CT/GC prevalence among older women suggests that PID etiology may not be similar across age groups.

Implications:
Higher prevalence among young PID cases supports screening of young women to identify upper and lower genital tract CT/GC. The high proportion of PID cases and the lower CT/GC prevalence among older women suggests that the etiology of PID may not be similar to that in younger women.